RKL Wealth Management LLC cut its position in shares of Pfizer Inc. (NYSE:PFE) by 19.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,957 shares of the biopharmaceutical company’s stock after selling 3,800 shares during the quarter. RKL Wealth Management LLC’s holdings in Pfizer were worth $583,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in PFE. Ballew Advisors Inc bought a new position in shares of Pfizer during the 1st quarter valued at about $102,000. W.G. Shaheen & Associates DBA Whitney & Co purchased a new stake in Pfizer during the 1st quarter valued at about $132,000. Bray Capital Advisors purchased a new stake in Pfizer during the 1st quarter valued at about $139,000. Braun Bostich & Associates Inc. purchased a new stake in Pfizer during the 1st quarter valued at about $139,000. Finally, Clearwater Capital Advisors LLC purchased a new stake in Pfizer during the 1st quarter valued at about $156,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.
In other Pfizer news, insider Frank A. Damelio sold 150,484 shares of the stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $40.00, for a total value of $6,019,360.00. Following the completion of the sale, the insider now owns 337,391 shares in the company, valued at approximately $13,495,640. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Kirsten Lund-Jurgensen sold 20,942 shares of the stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $40.04, for a total value of $838,517.68. Following the completion of the sale, the executive vice president now owns 20,185 shares of the company’s stock, valued at approximately $808,207.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 234,096 shares of company stock valued at $9,366,617. Company insiders own 0.06% of the company’s stock.
Several equities research analysts recently weighed in on the company. Barclays set a $40.00 target price on Pfizer and gave the company a “neutral” rating in a report on Friday. Cantor Fitzgerald restated a “buy” rating and set a $53.00 target price on shares of Pfizer in a report on Wednesday. Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Credit Suisse Group set a $40.00 target price on Pfizer and gave the company a “hold” rating in a report on Sunday, October 14th. Finally, ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Tuesday, October 9th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $42.80.
NYSE PFE opened at $44.50 on Friday. Pfizer Inc. has a fifty-two week low of $33.20 and a fifty-two week high of $45.81. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91. The company has a market capitalization of $265.32 billion, a price-to-earnings ratio of 16.79, a price-to-earnings-growth ratio of 2.28 and a beta of 0.96.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The business had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. During the same quarter last year, the business posted $0.67 EPS. The business’s revenue was up 4.4% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Shareholders of record on Friday, November 9th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.06%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Further Reading: How to Invest in Marijuana Stocks
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.